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Chronic obstructive pulmonary disease
AbstrAct
Introduction Chronic obstructive pulmonary disease (COPD) 
will soon be the third leading global cause of death and is 
increasing rapidly in low/middle-income countries. There is 
a need for local validation of the Saint George’s Respiratory 
Questionnaire (SGRQ), which can be used to identify those 
experiencing lifestyle impairment due to their breathing.
Methods The SGRQ was professionally translated into 
Luganda and reviewed by our field staff and a local 
pulmonologist. Participants included a COPD-confirmed 
clinic sample and COPD-positive and negative members of 
the community who were enrolled in the Lung Function in 
Nakaseke and Kampala (LiNK) Study. SGRQs were assembled 
from all participants, while demographic and spirometry data 
were additionally collected from LiNK participants.
results In total, 103 questionnaires were included in 
analysis: 49 with COPD from clinic, 34 community COPD-
negative and 20 community COPD-positive. SGRQ score 
varied by group: 53.5 for clinic, 34.4 for community 
COPD-positive and 4.1 for community COPD-negative 
(p<0.001). The cross-validated c statistic for SGRQ total 
score predicting COPD was 0.87 (95% CI 0.75 to 1.00). 
SGRQ total score was associated with COPD severity 
(forced expiratory volume in 1 s per cent of predicted), with 
an r coefficient of −0.60 (−0.75, −0.39). SGRQ score was 
associated with dyspnoea (OR 1.05/point; 1.01, 1.09) and 
cough (1.07; 1.03, 1.11).
conclusion Our Luganda language SGRQ accurately 
distinguishes between COPD-positive and negative 
community members in rural Uganda. Scores were 
correlated with COPD severity and were associated 
with odds of dyspnoea and cough. We find that it can 
be successfully used as a respiratory questionnaire for 
obstructed adults in Uganda.
bAckground
Chronic obstructive pulmonary disease 
(COPD) accounted for more than 3 million 
deaths globally in 2015, 5.3% of the world’s 
total.1 2 As the global burden of COPD 
increases, special attention must be paid to 
low/middle-income countries, which are 
experiencing a unique combination of risk 
factors: a growing elderly population, urban-
isation and increasing tobacco smoking.3 4 
Additionally, research investigating potential 
links between biomass fuel use and COPD 
is ongoing.5 6 It has been estimated that 
the African region experienced the second 
largest increase in COPD cases between 1990 
and 2010 (+102.1%, behind only Eastern 
Mediterranean among WHO regions).7
Within this population, there is a need for 
a simple tool to identify those who are expe-
riencing lifestyle impairment due to their 
breathing as part of a plan to diagnose and 
treat those experiencing chronic respiratory 
disease. The Saint George’s Respiratory Ques-
tionnaire (SGRQ) was designed to evaluate 
the health impacts of chronic respiratory 
disease, specifically asthma and COPD.8 It is 
comprised of three sections covering symp-
toms, physical activities and psychosocial 
impacts over a set preceding time period 
and has been shown to correlate to tests of 
exercise, breathlessness and anxiety/depres-
sion.8 Thus far, the SGRQ has been validated 
in over 60 languages. We aimed to translate 
the 3-month recall version of the SGRQ to 
Luganda and validate its relationship to airway 
obstruction in three samples of the Ugandan 
population: those from the community with 
no obstruction, those from the community 
with spirometry-confirmed COPD and those 
with clinic-confirmed COPD. We further 
attempted to determine the efficacy of the 
SGRQ as a screening tool for COPD, indi-
cating those who may require further care.
Methods
study setting
The data for this analysis were collected as 
part of the Lung Function in Nakaseke and 
Kampala (LiNK) study, for which the general 
Key messages
 ► Our Luganda translation of the Saint George’s 
Respiratory Questionnaire effectively distinguished 
between those with chronic obstructed pulmonary 
disease and those without. 
 ► SGRQ total scores were associated with COPD se-
verity and self-reported dyspnoea and cough. 
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methods are described elsewhere.9 Kampala, the capital 
of Uganda, has over 400 000 households and a population 
of around 1.5 million.10 Nakaseke is a rural health district 
with over 40 000 households and nearly 200 000 residents.10 
It includes a central periurban community and is situated 
approximately 50 km northwest of Kampala.
translation and validation
An initial forward translation of the SGRQ into the 
Luganda language was obtained from a local translator. 
This was back-translated and reviewed point by point by 
the LiNK staff and bilingual field staff, who made edits to 
ensure that the language was correct and that the spirit 
and cultural relevance of the questions was retained. The 
revised copy was reviewed by the local pulmonologist and 
further minor changes were made.
study design
The first language of more than 5.5 million people and 
spoken by over 6.5 million in Uganda (representing 17% 
of the 2014 population of 38.5 million), Luganda is the 
predominant Bantu language in southern and central 
regions of the country.11 As part of the LiNK study, our 
Luganda SGRQ was administered to participants from the 
community who tested positive for COPD in the field. For 
this analysis, fieldworkers were instructed to administer the 
Luganda SGRQ to a convenience sample of participants 
from the community who tested negative for COPD. We 
aimed to collect at least 30 SGRQ tests in each group in order 
to detect the 16.5-point difference reported in the Nepali 
SGRQ validation.12 Finally, a fieldworker was sent to the 
lung clinic of Mulago National Referral Hospital to recruit 
a set of 50 individuals with clinic-confirmed COPD. Inclu-
sion criteria included age ≥30 years and ability to provide 
informed consent. Exclusion criteria included pregnancy 
and report of active tuberculosis. Written informed consent 
was obtained. Spirometry was conducted according to Amer-
ican Thoracic Society/European Respiratory Society guide-
lines.13 All data were collected via Open Data Kit (University 
of Washington, Seattle, Washington) on tablet computers.
Table 1 Comparison of demographic factors between community COPD-positive and community COPD-negative 
participants.
COPD negative (63.0%, n=34) COPD positive (37.0%, n=20) P values
Demographics: % (n) or mean (SD)
  Age (years) 45.7 (8.92) 54.9 (13.6) 0.004
  Being female 64.7% (22) 40.0% (8) 0.08
  Body mass index (kg/m2) 26.4 (5.01) 20.0 (2.99) <0.001
  Primary education or less 76.5% (26) 95.0% (19) 0.08
  Household size >3 people 82.4% (28) 50.0% (10) 0.012
Risk factors: % (n)
  Current smoking 2.9 (1) 30.0 (6) 0.004
  Obesity (body mass index ≥30 kg/m2) 26.5 (9) 0 (0) 0.012
  Self-reported HIV 3.5 (1) 14.3 (2) 0.19
  Self-reported tuberculosis 3.9 (1) 20.0 (3) 0.09
  Household biomass use 97.1 (33) 100 (20) 0.44
Prebronchodilator spirometry: mean (SD)
  FEV1 (L) 2.50 (0.47) 1.57 (0.80) <0.001
  % Predicted 0.92 (0.13) 0.62 (0.23) <0.001
  FVC (L) 3.12 (0.50) 2.68 (1.16) 0.06
  % Predicted 0.93 (0.11) 0.84 (0.24) 0.05
  FEV1/FVC ratio 80.1 (6.69) 57.5 (9.98) <0.001
  % Predicted 0.99 (0.08) 0.72 (0.12) <0.001
Symptoms: % (n)
  Cough 9.1 (3) 35.0 (7) 0.019
  Phlegm 10.7 (3) 5.3 (1) 0.51
  Wheeze 7.1 (2) 10.5 (2) 0.68
  Dyspnoea with exertion 14.3 (4) 26.3 (5) 0.30
 P value represents results from t-test or Χ2 test.
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity. 
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definitions
The SGRQ comprises three subsections: the symptoms 
component covers the effects, frequency and severity 
of respiratory symptoms; the activity component covers 
daily activities that cause or are impaired by breathless-
ness; and the impact component covers social func-
tioning and the psychosocial disturbances associated with 
their respiratory disease.14 The total score, a combination 
of the three component scores, is presented as a scale 
of health impairment where 100 represents the worst 
possible health and 0 represents the best.14 All spiro-
metric predicted values are based on the National Health 
and Nutrition Examination Survey (NHANES) Afri-
can-American reference population.15 COPD was defined 
as a post-bronchodilator forced expiratory volume in 1 s/
forced vital capacity (FEV1/FVC) ratio less than the lower 
limit of normal (bottom 5th percentile of the reference 
population). Cough was defined as self-report of having 
cough daily or upon waking in the morning. Dyspnoea 
was defined as self-report of experience of shortness of 
breath with physical exertion. Wheeze was defined as 
self-report of the chest often sounding noisy (wheezy, 
whistling) when breathing. Phlegm was defined as self-re-
port of frequently coughing up mucus.
biostatistical methods
Baseline group differences were obtained via Χ2 or t-tests 
for categorical or continuous variables, respectively. 
Differences in total and component SGRQ scores between 
the community COPD-negative, community COPD-posi-
tive and clinic COPD-positive groups were obtained via 
analysis of variance tests. Adjusted differences between 
the community COPD-positive and negative groups were 
obtained via linear regression, controlling for age, sex 
and height. Validity of SGRQ total score and component 
categories as predictors of COPD status in the commu-
nity was assessed via unadjusted logistic modelling and 
receiver operating characteristic (ROC) curves. Based 
on this outcome, a cut point was chosen and agreement 
between SGRQ and COPD status using this cut point 
was established via Fleiss’ kappa test. The association 
between SGRQ score and COPD severity as defined by 
per cent predicted FEV1 was assessed via Pearson correla-
tion. Analyses were performed in Stata V.13 (StataCorp, 
College Station, Texas).
results
Participant characteristics
A collection of 49 SGRQs was gathered from the lung 
clinic of Mulago National Referral Hospital. Additionally, 
Figure 1 Boxplots of Saint George’s Respiratory Questionnaire (SGRQ) scores between groups. Top and bottom of box 
represent 75th and 25th percentiles of distribution. Horizontal bar represents median. Dots represent outlying data.
Table 2 Differences in SGRQ scores between 
community COPD-positive and community COPD-negative 
participants.
Single variable Multivariable*
Outcomes: difference in score
  Symptoms 27.5 (16.9–34.7) 29.3 (17.3–36.9)
  Activity 36.8 (23.6–47.4) 37.2 (22.7–47.8)
  Impacts 30.0 (19.9–37.5) 29.2 (18.1–37.4)
  Total 30.3 (21.3–39.2) 29.9 (20.2–39.6)
P value represents results from regression analyses.
*Multivariable models adjusted for age, sex and height.
COPD, chronic obstructive pulmonary disease; SGRQ, Saint 
George’s Respiratory Questionnaire. 
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a total of 54 adult participants from our community 
sample in Nakaseke, Uganda, were included in this anal-
ysis for a total sample of 103. Those from the community 
had a mean age of 49.1 years and were 55.6% female. 
Those with COPD were older, had a lower body mass 
index and were more likely to smoke (table 1). There was 
a 3.48 z score difference in FEV1/FVC ratio between the 
COPD-positive and COPD-negative community partic-
ipants (−3.48 vs 0.00; p<0.001). The only demographic 
difference between the sample and the parent cohort in 
Nakaseke was history of post-treatment pulmonary tuber-
culosis, with a higher prevalence among SGRQ sample 
participants (online supplementary table 1). The sample 
did differ in most ways from the parent cohort with 
respect to lung function, having generally worse scores 
from prebronchodilator spirometry, which was expected 
as it contains a much higher prevalence of participants 
with pulmonary obstruction. Our sample of COPD-pos-
itive community participants represents 50% of the 40 
identified during the LiNK study in Nakaseke. Those 
with COPD from the community who were included in 
our validation sample had slightly more severe obstruc-
tion (GOLD criteria) than those who were not included 
(online supplementary table 2).16
sgrQ scores between groups
SGRQ total score was highest for the clinic population, 
followed by the community COPD-positive and commu-
nity COPD-negative groups (figure 1). The same pattern 
was seen after breaking total score down into component 
segments: symptoms score, activity score and impacts 
score. Significant differences were found between 
each pairwise comparison of groups, both for total and 
component scores. In linear regression among commu-
nity participants, SGRQ scores were higher across the 
board for those who were COPD positive compared with 
those who were COPD negative (table 2). Further, SGRQ 
total score was higher (26.5 points, 95% CI 13.2 to 39.8) 
among those who smoked daily, adjusted for age, sex and 
height. SGRQ score was unable to be modelled against 
biomass fuel smoke exposure due to homogeneity of 
exposure (97.1% of sample used biomass fuels).
From single variable logistic regression and ROC anal-
ysis, the c statistic for total SGRQ score as a predictor of 
COPD status was 0.92 (95% CI 0.85 to 0.99) (figure 2). 
The c statistic for component SGRQ scores alone was 0.91 
(95% CI 0.83 to 0.98) for symptoms, 0.91 (95% CI 0.82 
to 0.99) for impacts and 0.85 (95% CI 0.74 to 0.96) for 
activities. Sensitivity analysis with 10-fold cross-validation 
revealed slightly lower though still strong c statistics: 0.87 
(95% CI 0.75 to 1.00) for SGRQ total score with compo-
nent scores ranging from 0.77 to 0.90. The optimal cut 
point for predicting COPD based on this sample was 
6.2 for both the Liu and Youden methods, which, when 
applied to the source sample, lead to a Fleiss’ kappa score 
for classification agreement of 0.72 (95% CI 0.45 to 0.99).
sgrQ and lung function
Total SGRQ score was linearly associated with COPD 
severity among all community participants, with a 
Figure 2 Receiver operating characteristic (ROC) curves for Saint George’s Respiratory Questionnaire (SGRQ) category 
scores predicting chronic obstructive pulmonary disease (COPD). Points represent combination of sensitivity and specificity 
of prediction of COPD at each value of SGRQ total and component score in analysis.
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Pearson’s correlation coefficient of −0.60 (95% CI 
−0.75 to −0.39) (online supplementary figure 1). After 
stratifying by group, no association was seen between 
SGRQ score and lung dysfunction among COPD-nega-
tive participants (r=0.09; 95% CI −0.27 to 0.42) while a 
negative correlation was retained among COPD-positive 
participants (r=−0.38; 95% CI −0.71 to 0.09).
sgrQ and symptoms
Adjusted by age and sex, SGRQ total score was a signifi-
cant linear predictor of dyspnoea (OR 1.05/point; 95% CI 
1.01 to 1.09), cough (OR 1.07; 95% CI 1.03 to 1.11) 
and phlegm (OR 1.08/point, 95% CI 1.02 to 1.14) and 
trended towards an association with wheeze (OR 1.04; 
95% CI 0.99 to 1.09) (figure 3 and online supplementary 
table 3). Within the component sections, symptom scores 
were positively associated with each respiratory outcome 
while activity and impact scores were associated with 
phlegm, cough, and dyspnoea alone.
dIscussIon
We developed and validated the SGRQ in Luganda. 
Significant differences were found in total and compo-
nent scores between COPD-positive and negative popu-
lation-sampled groups and we observe an ability to accu-
rately distinguish between the two in our sample. Further, 
we saw a correlation between increasing SGRQ scores 
and decreasing FEV1 per cent of predicted. We anticipate 
that it can be successfully used as a respiratory question-
naire for obstructed adults in Uganda.
Data on COPD in Uganda are limited to two studies: 
the LiNK study and the FRESH AIR study in Masindi.9 17 
Prevalence estimates for COPD range from 6% to 16%, 
yet the Clinical COPD Questionnaire—used in FRESH 
AIR—is the only validated measure assessing symptoms 
and quality of life in these areas.17 Our translation 
of the SGRQ was effective in discriminating between 
COPD-positive and negative participants in our sample 
from Nakaseke, Uganda. The c statistic of 0.92 for the 
SGRQ total score is high; however, it is expected to be 
high when applied to the same sample from which it 
was calculated. In sensitivity analyses using 10-fold 
cross-validation, the area under the curve remained 
high but was a more reasonable 0.88. The cross-val-
idated score remained much higher than the 0.77 
found by Sherpa et al and the 0.69 found by Weatherall 
et al.12 18 One potential contributing factor is that those 
studies used a fixed cut-off of 70% for FEV1/FVC ratio 
to define COPD whereas we chose to use the lower limit 
of normal based on the NHANES African-American 
reference population.15
Our finding of a strong correlation coefficient of 
−0.60 between SGRQ total score and FEV1 per cent of 
predicted for all participants mimics the results of other 
studies and indicates an important relationship between 
SGRQ score and severity of airway obstruction.8 18–21 
Within this, the −0.38 correlation coefficient we found 
Figure 3 Association of Saint George’s Respiratory Questionnaire (SGRQ) total and category scores with respiratory 
symptoms. The diamonds represent the increase in odds for having the respiratory symptom outcome based on a unit 
increase in SGRQ score from multivariable logistic regression analysis. The coloured bars represent the 95% CI of the 
estimate. All models are adjusted for age and sex.
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among COPD-positive community members falls within 
the range of −0.27 to −0.45 previously published.21–24
Although the method of modelling differed, our finding 
of a relationship between a higher SGRQ total score and OR 
of reporting dyspnoea with exertion agrees with previous 
studies reporting significant correlations between Saint 
George’s scores and measures of breathlessness.8 20 24–27 
Similarly, in this analysis, the SGRQ total score and all 
component scores were positively associated with cough, as 
found in the original SGRQ study by Jones and colleagues.8 
In our sample, only symptom component scores were asso-
ciated with wheezing, though previous studies had found 
relationships with total score and other components as 
well.8 26 
Our study has several strengths. Nesting within the LiNK 
study ensured high-quality data (through quality control 
measures) and standardised administration of spirom-
etry. The inclusion of both clinically validated COPD and 
community COPD-negative groups in addition to our 
community COPD-positive group allowed us to look at 
between-group trends in scoring, unlike validation studies 
which only included those with COPD.19–21 23 28 29 We were 
also capable of linking the SGRQ to reported symptoms, 
which was not often included in other validation studies. 
This analysis had some shortcomings as well. We did not 
collect demographic or lung function information on clinic 
participants (who were not enrolled in the LiNK study) so 
we were unable to include them in analyses concerning 
regressions or correlations. We also did not hit our initial 
target sample of COPD-positive community members 
before LiNK study recruitment ended due to restarting 
data collection secondary to scoring issues with our original 
version of the form. Even so, we were able to detect large 
differences between COPD-positive and negative groups 
as well as see a linear relationship between SGRQ score 
and breathing restriction severity. Finally, we were limited 
to cross-sectional data. This was sufficient for drawing the 
correlations we have laid out in this paper, but individual 
follow-up data would allow for a more detailed investiga-
tion into how SGRQ scores relate to changing lung func-
tion over time, including exacerbations.20 21 23 28 29
In summary, the Luganda translation of the SGRQ 
correlates well with airway obstruction and report of respira-
tory symptoms and can be an effective respiratory question-
naire for use in Uganda.
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